The DOI matches its Crossref record; 202 of the 205 references it cites were found in a registry or an index; 1 of the 287 sources its claims cite were checked for support.
Benzodiazepines in epilepsy: pharmacology and pharmacokinetics
Open accessAbstract
Benzodiazepines (BZDs) remain important agents in the management of epilepsy. They are drugs of first choice for status epilepticus and seizures associated with post-anoxic insult and are also frequently used in the treatment of febrile, acute repetitive and alcohol withdrawal seizures. Clinical advantages of these drugs include rapid onset of action, high efficacy rates and minimal toxicity. Benzodiazepines are used in a variety of clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes. Potential shortcomings of BZDs include tolerance, withdrawal symptoms, adverse events, such as cognitive impairment and sedation, and drug interactions. Benzodiazepines differ in their pharmacologic effects and pharmacokinetic profiles, which dictate how the drugs are used. Among the approximately 35 BZDs available, a select few are used for the management of seizures and epilepsy: clobazam, clonazepam, clorazepate, diazepam, lorazepam and midazolam. Among these BZDs, clorazepate has a unique profile that includes a long half-life of its active metabolite and slow onset of tolerance. Additionally, the pharmacokinetic characteristics of clorazepate (particularly the sustained-release formulation) could theoretically help minimize adverse events. However, larger, controlled studies of clorazepate are needed to further examine its role in the treatment of patients with epilepsy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
192 Not checked yet · 37 No basis given · 8 Own interpretation · 8 Own result · 1 Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“they suggested that longer than 6 months may be needed for recovery from some deficits.”
What the sources say
- Supportedcites [170] Barker, 2004, Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis, Arch Clin Neuropsychol source
The Discussion states that the data do not support full cognitive recovery in the first 6 months after cessation and suggests that some deficits may take longer than 6 months to recover. This directly supports the citing sentence’s hedged wording. (LLM, conf=0.95)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite the long half-life of DMD, a missed dayÕs dosing can result in altered peak-to-trough concentration ratios.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, the differences between peak and trough plasma DMD concentrations after a missed daily dose of clorazepate increased more with the immediate-release formulation than with the sustained-release formulation (Table 4).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the effect was modest, the sustained-release tablet maintained higher trough concentrations after a missed daily dose and replacement of the missed dose.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was little difference between the two formulations in peak and trough concentrations following a missed dayÕs dose.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Peak ⁄ trough difference b after missed dose(s) (lg ⁄ ml) | NA | 0.18 | 0.41 | NA | 0.18 | 0.42”
What the sources say
- Not checked yetcites [71] Riss
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Among the approximately 35 BZDs available, a select few are used for the management of seizures and epilepsy: clobazam, clonazepam, clorazepate, diazepam, lorazepam and midazolam.”
- Also stated in: § Introduction · plain
“few of the approximately 35 BZDs available worldwide (2) are used for managing epilepsy.”
What the sources say
- Not checked yetcites [2] International Narcotics Control Board
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
In the paper
“Midazolam is an exception, with low oral bioavailability due to metabolism by cytochrome P-450 (CYP) enzyme 3A5 in intestinal epithelial tissue, which can reduce by up to 50% the fraction of the dose reaching the bloodstream (24).”
What the sources say
- Not checked yetcites [24] Anderson, 2002
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines have differences in their physiochemical properties, most notably lipid solubility, which influence their rate of absorption and diffusion into tissue compartments and their pharmacokinetics.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The CYP isoenzymes catalyzing these reactions include 3A4, 3A5, 2B6, 2C9 and 2C19 (Tables 2 and 3).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 106
- Probably not a substantial claim. 28
- The quote only partly states this claim. 4
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, when a missed dayÕs dose of the sustainedrelease formulation was simulated, peak-to-trough differences increased by 0.01 lg ⁄ ml (5.9%) with no dose replacement and increased by 0.24 lg ⁄ ml (141.2%) with replacement of the missed dose (Table 4).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The time to maximum concentration was 2.43 and 9.20 h for the immediate-release and sustained-release formulations respectively.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When a missed dayÕs dose of the immediate-release formulation was simulated, peak-to-trough differences (compared with steady state) increased by 0.05 lg ⁄ ml (38.5%) with no dose replacement and increased by 0.29 lg ⁄ ml (223.1%) with replacement of the missed doses (Table 4).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean steady-state plasma DMD concentration was approximately 0.71 lg ⁄ ml for the immediaterelease formulation and 0.73 lg ⁄ ml for the sustained-release”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Change in trough plasma DMD concentrations (%) | NA | )44.1 | )41.9 | NA | )48.8 | )48.8”
What the sources say
- Not checked yetcites [71] Riss
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Peak ⁄ trough difference b at steady state (lg ⁄ ml) | 0.17 | NA | NA | 0.13 | NA | NA”
What the sources say
- Not checked yetcites [71] Riss
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Change in peak plasma DMD concentrations (%) | NA | )29.6 | 6.0 | NA | )27.1 | 9.6”
What the sources say
- Not checked yetcites [71] Riss
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Peak ⁄ trough difference b after missed dose(s) (lg ⁄ ml) | NA | 0.18 | 0.41 | NA | 0.18 | 0.42”
What the sources say
- Not checked yetcites [71] Riss
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Change in peak plasma DMD concentrations (%) | NA | )29.6 | 6.0 | NA | )27.1 | 9.6”
What the sources say
- Not checked yetcites [71] Riss
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Change in trough plasma DMD concentrations (%) | NA | )44.1 | )41.9 | NA | )48.8 | )48.8”
What the sources say
- Not checked yetcites [71] Riss
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“are also frequently used in the treatment of febrile, acute repetitive and alcohol withdrawal seizures”
- Also stated in: § Introduction · plain
“Benzodiazepines also continue to play major roles in treating other conditions such as febrile seizures, acute repetitive seizures and alcohol withdrawal seizures.”
What the sources say
- Not checked yetcites [81] Ko, 1997
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Introduction · plain
In the paper
“Benzodiazepines are used in a variety of clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes.”
- Also stated in: § Efficacy · plain
“Benzodiazepines are versatile drugs that can be employed in a variety of clinical settings because of their broad spectrum of activity and multiple formulations and because they can be administered by several routes”
What the sources say
- Not checked yetcites [81] Ko, 1997
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Clinical advantages of these drugs include rapid onset of action, high efficacy rates and minimal toxicity.”
- Also stated in: § Introduction · plain
“The major clinical advantages of BZDs are high efficacy rates, rapid onset of action and minimal toxicity.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
- Also stated in: § Introduction · plain
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines (BZDs) remain important agents in the management of epilepsy.They are drugs of first choice for status epilepticus and seizures associated with post-anoxic insult”
- Also stated in: § Introduction · plain
“Nonetheless, benzodiazepines (BZDs), which have been used since the 1960s, remain important in epilepsy management and are the drugs of first choice for status epilepticus and seizures associated with postanoxic insult.”
What the sources say
- Not checked yetcites [77] Alldredge, 2001, A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus, N Engl J Med source
- Not checked yetcites [78] Shaner, 1988, Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin, Neurology source
- Not checked yetcites [79] Treiman, 1998, A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Introduction · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines differ in their pharmacologic effects and pharmacokinetic profiles, which dictate how the drugs are used.”
- Also stated in: § Introduction · hedged
“Thus, pharmacokinetic differences often dictate the use of specific BZDs, route(s) of administration and formulation(s).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Introduction · hedged
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Potential shortcomings of BZDs include tolerance, withdrawal symptoms, adverse events, such as cognitive impairment and sedation, and drug interactions.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Clobazam is an exception with its 1-5-BZD structure (17).”
What the sources say
- Not checked yetcites [17] Shorvon, 1995
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“When orally administered, most BZDs are extensively and rapidly absorbed, with bioavailabilities varying from 80% to 100% and times to peak concentration ranging from minutes to several hours (Table 1).”
What the sources say
- Not checked yetcites [24] Anderson, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Transmitter-gated chloride channels, GABA C receptors, are selectively activated by certain conformationally restricted GABA analogs and are not modulated by steroids, BZDs or barbiturates (3).”
What the sources say
- Not checked yetcites [3] Chebib, 1999, The ABC of GABA receptors: a brief review, Clin Exp Pharmacol Physiol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Benzodiazepines also have large volumes of distribution, are highly bound to plasma proteins (Table 1) and readily cross into the placenta and breast milk (25).”
What the sources say
- Not checked yetcites [25] Hobbs, 1996
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, the pharmacokinetic characteristics of clorazepate (particularly the sustained-release formulation) could theoretically help minimize adverse events.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Diazepam and lorazepam are primarily used for management of seizure emergencies, whereas clobazam, clonazepam and clorazepate are commonly used in chronic epilepsy management.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The inhibitory neurotransmitter GABA binds to the receptor to open the chloride ion gates and produce an inhibitory current (6,8).”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Ligand-activated ion channels that are selectively blocked by bicuculline and modulated by steroids, BZDs, and barbiturates are known as GABA A receptors (3).”
What the sources say
- Not checked yetcites [3] Chebib, 1999, The ABC of GABA receptors: a brief review, Clin Exp Pharmacol Physiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Among these BZDs, clorazepate has a unique profile that includes a long half-life of its active metabolite and slow onset of tolerance.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines differ in their rates of elimination and the formation of pharmacologically active metabolites (Table 2).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The basic chemical structure of BZDs is formed from the fusion of a benzene ring and a sevenmembered diazepine ring (16) (Fig. 1).”
What the sources say
- Not checked yetcites [16] Feldman, 1997
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines allosterically bind to the receptor at a different location than GABA does and enhance the chloride channelÕs conductance by increasing the frequency of gated channel opening (6,7,(10)(11)(12).”
What the sources say
- Not checked yetcites [6] Macdonald, 1994, GABAA receptor channels, Annu Rev Neurosci source
- Not checked yetcites [7] McKernan, 1996, Which GABAA-receptor subtypes really occur in the brain?, Trends Neurosci source
- Not checked yetcites [10] Atack, 2006, Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA5-selective compound L-655,708, Drug Metab Dispos source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“There are three principal c-aminobutyric acid (GABA) receptor subtypes.”
What the sources say
- Not checked yetcites [3] Chebib, 1999, The ABC of GABA receptors: a brief review, Clin Exp Pharmacol Physiol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The GABA A receptor consists of a pentameric structure with multiple subunits that are necessary for normal physiologic function.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Midazolam often is used as an alternative to diazepam and lorazepam in seizure emergencies and for treating refractory status epilepticus.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Following rapid uptake, BZDs redistribute into less well-perfused tissues; the rate of redistribution is the fastest for the most lipid-soluble drugs (25).”
What the sources say
- Not checked yetcites [25] Hobbs, 1996
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Based on in vivo point mutations, a-1-GABA A receptors have been found to mediate sedation and anterograde amnesia and to partially mediate anticonvulsant activity, whereas a-2-GABA A receptors mediate anxiolysis (14,15).”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The second receptor subtype, GABA B , consists of G-protein-coupled, seven-transmembrane receptors, which are selectively activated by (R)-())baclofen and 3-aminopropylphosphinic acid and are blocked by phaclofen (3).”
What the sources say
- Not checked yetcites [3] Chebib, 1999, The ABC of GABA receptors: a brief review, Clin Exp Pharmacol Physiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There are, however, differences among BZDs in affinity for receptor subtypes, which may produce different pharmacologic effects.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines are classified as low, medium (e.g.clorazepate and diazepam) or high (e.g.clonazepam and lorazepam) potency (18,19).”
What the sources say
- Not checked yetcites [18] Nelson, 1999, Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal, Can J Clin Pharmacol
- Not checked yetcites [19] Chouinard, 2004, Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound, J Clin Psychiatry
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The receptor subunits are assembled from combinations of 19 polypeptides (i.e.a1-6, b1-3, c1-3, d, e, p, h and q1-3) (4); different subunit combinations determine the pharmacologic properties of the receptor (5,6).”
What the sources say
- Not checked yetcites [4] Simon, 2004, Analysis of the set of GABAA receptor genes in the human genome, J Biol Chem source
- Not checked yetcites [5] Sieghart, 1999, Structure and subunit composition of GABAA receptors, Neurochem Int source
- Not checked yetcites [6] Macdonald, 1994, GABAA receptor channels, Annu Rev Neurosci source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Benzodiazepines cross the blood-brain barrier rapidly, although the diffusion rate into the brain varies by drug and is largely determined by lipophilicity (21).”
What the sources say
- Not checked yetcites [21] Rey, 1999, Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes, Clin Pharmacokinet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In neonates, the t 1 ⁄ 2 of clorazepate is prolonged and clearance is decreased (67).”
What the sources say
- Not checked yetcites [67] Rey, 1979, Pharmacokinetics of the placental transfer and distribution of clorazepate and its metabolite nordiazepam in the feto-placental unit and in the neonate, Eur J Clin Pharmacol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Additionally, many elderly individuals take multiple medications, which increase their risk of drug-drug interactions.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Increased sensitivity of older patients to BZDs is partly due to reduced drug metabolism (when compared with younger adults), which can result in drug accumulation (62).”
What the sources say
- Not checked yetcites [62] Demaagd, 1995, High-risk drugs in the elderly population, Geriatr Nurs source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clonazepam and lorazepam undergo extensive metabolism, but no active metabolites are formed (18,24).”
What the sources say
- Not checked yetcites [18] Nelson, 1999, Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal, Can J Clin Pharmacol
- Not checked yetcites [24] Anderson, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“By contrast, clorazepate undergoes rapid and complete chemical conversion to DMD in the gastrointestinal tract; its pharmacologic effects are largely due to DMD (24,56).”
What the sources say
- Not checked yetcites [24] Anderson, 2002
- Not checked yetcites [56] Breimer, 1980, Pharmacokinetics of benzodiazepines. Short-acting versus long-acting, Arzneimittelforschung
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, BZD pharmacologic effects appear to be greater in elderly patients than in younger patients even at similar plasma BZD concentrations (63,64), possibly because of age-related changes in drug-receptor interactions, post-receptor mechanisms and organ function.”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As discussed earlier, BZD metabolism is complex and largely catalyzed by CYP isoenzymes.Consequently, there is potential for interactions between BZDs and drugs that induce or inhibit CYP isoenzymes.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Oral contraceptive steroids may inhibit the metabolism of some BZDs that undergo oxidative metabolism or nitroreduction and accelerate the metabolism of some BZDs that are conjugated.”
What the sources say
- Not checked yetcites [60] Back, 1990, Pharmacokinetic drug interactions with oral contraceptives, Clin Pharmacokinet source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Some BZDs are also available as oral liquids [diazepam (Diazepam Intensol; 5 mg ⁄ ml), lorazepam (Lorazepam Intensol; 2 mg ⁄ ml) and midazolam (generic only; 2 mg ⁄ ml)], disintegrating tablets [clonazepam (Klonopin Ò Wafer; Roche Pharmaceuticals, Nutley, NJ, USA; 0.125-, 0.25-, 0.5-, 1-and 2-mg tablets)] or a rectal gel [diazepam (Diastat Ò AcuDial; Valeant Pharmaceuticals International, Costa M”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“For example, inhibition of a minor pathway may have little impact on drug concentration, whereas inhibition of a major pathway may result in enhanced clinical effect or toxicity.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Cytochrome P-450-catalyzed metabolism tends to be low at birth, but exceeds adult values by age 2-3 years; thereafter, CYP-catalyzed metabolism decreases, reaching adult levels around puberty (66).”
What the sources say
- Not checked yetcites [66] Anderson, 2002, Children versus adults: pharmacokinetic and adverse-effect differences, Epilepsia source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Midazolam is rapidly converted by CYP 3A4 and CYP 3A5 to 1-hydroxymidazolam, which contributes approximately 10% to the biologic activity of its parent drug (24,41).”
What the sources say
- Not checked yetcites [24] Anderson, 2002
- Not checked yetcites [41] Gorski, 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily, Biochem Pharmacol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Elderly individuals often have variable drug absorption, decreased plasma protein-drug binding due to lower albumin concentrations, and reduced hepatic and renal clearance (61).”
What the sources say
- Not checked yetcites [61] Patsalos, 2002, The importance of drug interactions in epilepsy therapy, Epilepsia source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Extended-release drug formulations can help patients with epilepsy achieve their primary treatment goals of controlling seizures while reducing side effects by minimizing fluctuations in drug concentration and by improving compliance.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the Veterans Affairs cooperative study of status epilepticus, lorazepam terminated seizures in 64.9% of patients and was significantly more effective than phenytoin (P = 0.002) (79).”
What the sources say
- Not checked yetcites [79] Treiman, 1998, A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Fewer studies have evaluated the clinical efficacy of BZDs in chronic epilepsy.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Results from four comparative studies (three of blinded design) have suggested that lorazepam is superior to phenytoin and as effective as clonazepam, diazepam or the combination of diazepam and phenytoin in the initial treatment of status epilepticus (77,79,80,96).”
What the sources say
- Not checked yetcites [77] Alldredge, 2001, A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus, N Engl J Med source
- Not checked yetcites [79] Treiman, 1998, A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group, N Engl J Med source
- Not checked yetcites [80] Leppik, 1983, Double-blind study of lorazepam and diazepam in status epilepticus, JAMA source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines were used in epilepsy management as early as 1965, when Gastaut et al. (73,74) administered i.v.diazepam to treat status epilepticus.”
What the sources say
- Not checked yetcites [73] Gastaut, 1965, Treatment of status epilepticus with diazepam (Valium), Epilepsia source
- Not checked yetcites [74] Gastaut, 1965, Laction du diazepam (Valium) dans le traitement des formes non-convulsive de lepilepsie generalisee [in French], Rev Neurol (Paris)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines are among the most useful AEDs available for treating status epilepticus and acute repetitive seizures and for febrile seizure prophylaxis.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, when a missed daily dose was replaced, the sustainedrelease formulation resulted in a smaller change in peak concentrations, which may reduce the risk of drug toxicity.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Changes in simulated plasma DMD peak-to-trough concentrations correspond to clinical risks of breakthrough seizures and drug toxicity.
In the paper
“Therefore, multiple injections or continuous infusion may be required, which can lead to drug accumulation and possibly to acute respiratory depression, sedation and hypotension (76).”
What the sources say
- Not checked yetcites [76] Schmidt, 2002
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Diazepam is a drug of first choice for treatment of early status epilepticus and acute repetitive seizures and for febrile seizure prophylaxis.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In one study, 70% of children with absence seizures treated with clonazepam (seven of 10) had a ‡ 75% reduction in seizure frequency after 8 weeks of treatment, and an additional 10% of children (one of 10) had a 30% reduction in seizure frequency (105).”
What the sources say
- Not checked yetcites [105] Dreifuss, 1975, Serum clonazepam concentrations in children with absence seizures, Neurology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In a randomized trial comparing buccal midazolam with rectal diazepam in children, the drugs showed similar efficacy and onset of action (125).”
What the sources say
- Not checked yetcites [125] Scott, 1999, Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although it is used for many seizure types, midazolam does not have an FDA-approved indication for seizures.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Therapeutic success (defined as cessation of visible signs of seizure activity within 10 min of drug administration, lack of respiratory depression and no further seizures within 1 h) was noted in 56% of midazolam-treated patients (61 of 109) and 27% of diazepam-treated patients (30 of 110), a 29% difference between groups; (95% confidence interval, 16-41%).”
What the sources say
- Not checked yetcites [134] McIntyre, 2005, Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In that study, seizure cessation was achieved in 75% of cases ( 30 of 40)with midazolam and in 59% of cases (23 of 39) with diazepam treatment (P = 0.16).”
What the sources say
- Not checked yetcites [125] Scott, 1999, Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Although not currently approved in the USA, clobazam is commonly used elsewhere as adjunctive therapy for patients with refractory epilepsy (103).”
What the sources say
- Not checked yetcites [103] Trimble, 2002, On the use of tranquillisers in epilepsy, Epilepsia source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Midazolam is the only available water-soluble BZD; solubility is achieved when the injectable solution is buffered to a pH of 2.9-3.7 (123).”
What the sources say
- Not checked yetcites [123] 123.Midazolam HCl injection [package insert]. Weston, FL: Apotex Corp, 2000.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clobazam was studied in a large double-blind trial as first-line monotherapy in children with partial, partial with secondary generalization or primary generalized tonic-clonic seizures and was reported to have efficacy and tolerability similar to that of monotherapy with phenytoin or carbamazepine (153, 154).”
What the sources say
- Not checked yetcites [153] Canadian Study Group for Childhood Epilepsy, 1998, Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy, Epilepsia source
- Not checked yetcites [154] Bawden, 1999, The cognitive and behavioural effects of clobazam and standard monotherapy are comparable, Epilepsy Res source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Open-label studies have suggested that intranasal midazolam is safe and effective for acute seizure management in children (124, 127, 128, 135, 136).”
What the sources say
- Not checked yetcites [124] Lahat, 2000, Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study, BMJ source
- Not checked yetcites [127] Fisgin, 2002, Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study, J Child Neurol source
- Not checked yetcites [128] Mahmoudian, 2004, Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children, Epilepsy Behav source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“with 88% of seizures (23 of 26) responding to initial treatment with midazolam and 92% (24 of 26) responding to diazepam (124).”
What the sources say
- Not checked yetcites [124] Lahat, 2000, Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study, BMJ source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It is highly effective as adjunctive therapy for partial and generalized seizures, for intermittent therapy and for controlling nonconvulsive status epilepticus”
What the sources say
- Not checked yetcites [140] Shorvon, 1998, The use of clobazam, midazolam, and nitrazepam in epilepsy, Epilepsia source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“studies have suggested that intranasal midazolam is safe and effective for acute seizure management in children (124, 127, 128, 135, 136).”
What the sources say
- Not checked yetcites [124] Lahat, 2000, Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study, BMJ source
- Not checked yetcites [127] Fisgin, 2002, Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study, J Child Neurol source
- Not checked yetcites [128] Mahmoudian, 2004, Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children, Epilepsy Behav source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Additionally, pain is common with intranasal midazolam administration, which may indicate irritation of the nasal mucosa due to the low pH (3-4.3) of the formulation (137-139).”
What the sources say
- Not checked yetcites [137] Scott, 2001, Intranasal midazolam for treating febrile seizures in children. Buccal midazolam should be preferred to nasal midazolam [letter], BMJ source
- Not checked yetcites [138] Loftsson, 2001, Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray, Int J Pharm source
- Not checked yetcites [139] Gudmundsdttir, 2001, Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans, Pharmazie
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A large volume is required to deliver a therapeutic dose, making administration difficult because much of the solution may leak out of the nose or be swallowed (137).”
What the sources say
- Not checked yetcites [137] Scott, 2001, Intranasal midazolam for treating febrile seizures in children. Buccal midazolam should be preferred to nasal midazolam [letter], BMJ source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Paradoxical excitement is sometimes associated with BZD use and may include exacerbation of seizures in patients with epilepsy (171).”
What the sources say
- Not checked yetcites [171] Gayatri, 2006, Aggravation of epilepsy by anti-epileptic drugs, Dev Med Child Neurol source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“and although diazepam impairs explicit memory, results regarding impairment of implicit memory by diazepam are mixed (176-179).”
What the sources say
- Not checked yetcites [176] Legrand, 1995, Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory, Psychopharmacology source
- Not checked yetcites [177] Wagemans, 1998, Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments, Psychopharmacology source
- Not checked yetcites [178] Vidailhet, 1994, Lorazepam and diazepam effects on memory acquisition in priming tasks, Psychopharmacology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Benzodiazepine use is also associated with falls, a possible result of over-sedation in elderly patients (167).”
What the sources say
- Not checked yetcites [167] Souchet, 2005, Drug related falls: a study in the French pharmacovigilance database, Pharmacoepidemiol Drug Saf source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Over-sedation is more problematic in the elderly than in younger patients, and it may occur at lower doses in the elderly (165, 166).”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“High BZD dosage and potency, short duration of BZD action, long duration of therapy and premorbid dependent personality traits are risk factors for the development of BZD dependence (173).”
What the sources say
- Not checked yetcites [173] Marriott, 1993, Benzodiazepine dependence. Avoidance and withdrawal, Drug Saf source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lorazepam appears to impair both explicit memory and implicit memory”
What the sources say
- Not checked yetcites [176] Legrand, 1995, Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory, Psychopharmacology source
- Not checked yetcites [177] Wagemans, 1998, Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments, Psychopharmacology source
- Not checked yetcites [178] Vidailhet, 1994, Lorazepam and diazepam effects on memory acquisition in priming tasks, Psychopharmacology source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“For individuals who use BZDs long term, the possible degree of recovery and the extent of residual impairment that may remain after the drugs are withdrawn are unclear (170).”
What the sources say
- Not checked yetcites [170] Barker, 2004, Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis, Arch Clin Neuropsychol source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This effect is sometimes deliberately utilized in presurgical medication (169).”
What the sources say
- Not checked yetcites [169] Ranta, 2002, Patients conscious recollections from cardiac anesthesia, J Cardiothorac Vasc Anesth source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Additionally, although BZDs are generally known to affect memory, some studies have shown that effects differ depending on the BZD used.”
What the sources say
- Not checked yetcites [176] Legrand, 1995, Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory, Psychopharmacology source
- Not checked yetcites [177] Wagemans, 1998, Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments, Psychopharmacology source
- Not checked yetcites [178] Vidailhet, 1994, Lorazepam and diazepam effects on memory acquisition in priming tasks, Psychopharmacology source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In that study, an excellent response (defined as complete seizure control or seizure control that produced a notable improvement in social, educational or vocational assessment) was observed for 19% of patients with major generalized seizures (three of 16), 39% of patients with absence seizures (seven of 18), 33% of patients with akinetic seizures (three of nine) and 57% of patients with myoclonic”
What the sources say
- Not checked yetcites [155] Booker, 1974, Clorazepate dipotassium in the treatment of intractable epilepsy, JAMA source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Elderly patients treated with BZDs can experience confusion, amnesia, ataxia and hangover effects (62).”
What the sources say
- Not checked yetcites [62] Demaagd, 1995, High-risk drugs in the elderly population, Geriatr Nurs source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Young et al. (185) found that tolerance to clobazam developed within 3 days of initial drug exposure, whereas tolerance to clonazepam developed gradually over the course of a 19-day study.”
What the sources say
- Not checked yetcites [185] Young, 1988, Differences in the development of tolerance to two anticonvulsant benzodiazepines in the amygdaloid kindled rat, J Pharm Pharmacol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Other shortcomings include adverse events, such as cognitive impairment and sedation, and drug interactions.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“The authors suggested that differences in tolerance and crosstolerance could result from differential regulation of receptor subunit expression by each drug and from differences between the drugs in their interactions with receptors at the time of testing.”
What the sources say
- Not checked yetcites [187] Ramsey-Williams, 1994, Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam, Pharmacol Biochem Behav source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“They have the clinical advantages of being highly effective, with a rapid onset of action and relatively low toxicity.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Rats treated with midazolam for 3 weeks developed cross-tolerance to diazepam but not to clobazam or clonazepam.”
What the sources say
- Not checked yetcites [187] Ramsey-Williams, 1994, Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam, Pharmacol Biochem Behav source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines can be used in a variety of clinical situations because they can be administered by several routes and in different formulations.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“When BZDs are used as anticonvulsants, the time to onset of tolerance varies, and the potential of a BZD to induce anticonvulsant tolerance does not appear to have any relationship with its chemical or pharmacokinetic properties (188).”
What the sources say
- Not checked yetcites [188] Garratt, 1988, Can benzodiazepines be classified by characterising their anticonvulsant tolerance-inducing potential?, Eur J Pharmacol source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Cross-tolerance between BZDs occurs and appears to be drug specific.”
What the sources say
- Not checked yetcites [187] Ramsey-Williams, 1994, Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam, Pharmacol Biochem Behav source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Clobazam | Demethylation (26) | N-desmethylclobazam (27) | 10-30 (28) | 36-46 (28)”
What the sources say
- Not checked yetcites [28] Rupp, 1979, Pharmacokinetics of single and multiple doses of clobazam in humans, Br J Clin Pharmacol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clonazepam | Nitroreduction (CYP 3A4), | NA | 19-60 (32) | NA”
What the sources say
- Not checked yetcites [29] Seree, 1993, Fundam Clin Pharmacol source
- Not checked yetcites [30] Miller, 1981, Clonazepam acetylation in fast and slow acetylators, Clin Pharmacol Ther source
- Not checked yetcites [31] Peng, 1984, Polymorphic acetylation of 7-amino-clonazepam in human liver cytosol, Pediatr Pharmacol (New York)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Clorazepate is unique among BZDs in that it is associated with slow onset of tolerance, its active metabolite has a long t 1 ⁄ 2 , and it is available as a sustained-release formulation”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines are indicated for the treatment of seizure emergencies and epilepsy.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Studies of clorazepate in patients with epilepsy have mainly been small, open-label investigations.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“Gobbi et al. (199) demonstrated that diazepam and DMD have the same affinity for the central type of BZD receptors, but when the intrinsic activity of DMD was calculated, it proved to be a partial agonist, with intrinsic activity approximately 43% that of diazepam.”
What the sources say
- Not checked yetcites [199] Gobbi, 1987, Diazepam and desmethyldiazepam differ in their affinities and efficacies at central and peripheral benzodiazepine receptors, J Pharm Pharmacol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“One putative mechanism for the development of tolerance is simple down-regulation of GABA receptors in response to prolonged BZD exposure; however, studies testing this hypothesis have reported mixed results (197).”
What the sources say
- Not checked yetcites [197] Bateson, 2002, Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal, Curr Pharm Des source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Several other mechanisms for BZD tolerance have been proposed on the basis of animal and cell culture models.These processes include uncoupling of allosteric linkage between GABA and BZD sites, changes in the turnover of receptor subunits and changes in receptor gene expression (197).”
What the sources say
- Not checked yetcites [197] Bateson, 2002, Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal, Curr Pharm Des source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“all of which may, theoretically, help minimize adverse effects and withdrawal symptoms.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Li et al. (198) suggested that down-regulation of BZD receptor binding sites could not fully explain the development of tolerance because tolerance to some BZDs has been observed even when no changes in BZDreceptor binding were noted (187).”
What the sources say
- Not checked yetcites [198] Li, 2000, Down-regulation of benzodiazepine binding to alpha-5 subunit-containing gamma-aminobutyric acidA receptors in tolerant rat brain indicates particular involvement of the hippocampal CA1 region, J Pharmacol Exp Ther
- Not checked yetcites [187] Ramsey-Williams, 1994, Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam, Pharmacol Biochem Behav source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“However, results from other studies have suggested that, compared with long-t 1 ⁄ 2 BZDs, BZDs with short t 1 ⁄ 2 are associated with faster onset of withdrawal symptoms or more severe withdrawal symptoms when BZD therapy is stopped abruptly (211, 212).”
What the sources say
- Not checked yetcites [211] Rickels, 1990, Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation [erratum in Arch Gen Psychiatry 1991;48:51], Arch Gen Psychiatry source
- Not checked yetcites [212] Busto, 1986, Withdrawal reaction after long-term therapeutic use of benzodiazepines, N Engl J Med source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clobazam | Demethylation (26) | N-desmethylclobazam (27) | 10-30 (28) | 36-46 (28)”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clorazepate | Decarboxylation, glucuronidation, | DMD (major), oxazepam (minor) (24) | NA | 20-160 (24, 33, 34)”
What the sources say
- Not checked yetcites [24] Anderson, 2002
- Not checked yetcites [33] Greenblatt, 1988, Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam, J Clin Pharmacol source
- Not checked yetcites [34] Bertler, 1980, Pharmacokinetics of dipotassium chlorazepate in patients after repeated 50mg oral doses, Psychopharmacology (Berl) source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, tolerance may recur at the higher dose, and adverse effects may persist or worsen.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Tolerance may develop over time, making BZDs unsuitable for use in long-term epilepsy management.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Rosenberg et al. (189) compared the anticonvulsant activity of clonazepam, clobazam and diazepam in rats and found that tolerance developed most rapidly to clobazam and most slowly to clonazepam.”
What the sources say
- Not checked yetcites [189] Rosenberg, 1989, Tolerance to anticonvulsant effects of diazepam, clonazepam, and clobazam in amygdala-kindled rats, Epilepsia source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Additionally, withdrawal symptoms, some severe, may develop after cessation of BZD therapy.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“Considering the evidence that tolerance to the various behavioral effects of BZDs develops at different rates and that behavioral effects of BZDs are mediated by different GABA A receptor subtypes, Bateson (197) proposed that multiple mechanisms mediate tolerance and dependence.He described a unified model of molecular mechanisms underlying tolerance that incorporates the molecular processes”
What the sources say
- Not checked yetcites [197] Bateson, 2002, Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal, Curr Pharm Des source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- The authors state this as an assumption: In Bateson's unified model, initial potentiation of the GABA response leads to desensitization, and prolonged desensitization could result in uncoupling as either a signal for or a consequence of receptor internalization.
- The authors state this as an assumption: After receptor internalization, degradation of certain receptor subunits could provide a signal for changes in GABA A receptor gene transcription.
In the paper
“Tolerance occurred in 48% of patients treated with clorazepate for ‡4 weeks, but in only 24% of patients treated with clobazam for ‡3 months (193).”
What the sources say
- Not checked yetcites [193] Sugai, 2004, Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan, Epilepsia source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Some reports have suggested that BZD t 1 ⁄ 2 does not influence withdrawal symptoms (208, 210).”
What the sources say
- Not checked yetcites [208] Schweizer, 1990, Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper, Arch Gen Psychiatry source
- Not checked yetcites [210] Murphy, 1991, A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence, Br J Psychiatry source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Numerous reports have identified certain predictors of the occurrence or increased severity of withdrawal symptoms: higher BZD dose (200-204), longer duration of BZD use (202, 203, 205, 206), immediate cessation or rapid tapering of the BZD dose (200, 203, 204, 207-209), history of drug abuse (202, 203), dependence on other drugs (209), personality pathology (e.g.neuroticism and dependency) (203)”
What the sources say
- Not checked yetcites [200] Martnez-Cano, 1995, Benzodiazepine withdrawal syndrome seizures, Pharmacopsychiatry source
- Not checked yetcites [202] Uhlenhuth, 1999, International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders, J Clin Psychopharmacol source
- Not checked yetcites [203] Schweizer, 1998, Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management, Acta Psychiatr Scand Suppl source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clorazepate | Tranxene T-Tab | Yes | Anxiety, alcohol withdrawal, | Adjunctive treatment of partial seizures (75)”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clobazam | Frisium | NA | Not FDA approved | First-line adjunctive treatment for treatment-resistant”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lorazepam | Glucuronidation (24) | NA | 7-26 (39, 40) | NA”
What the sources say
- Not checked yetcites [24] Anderson, 2002
- Not checked yetcites [39] Greenblatt, 1979, Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans, J Pharm Sci source
- Not checked yetcites [40] Greenblatt, 1982, Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam, J Pharm Sci source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Diazepam | Demethylation (CYP 2C9, 2C19, 2B6, 3A4, | DMD (major), oxazepam (minor), | 21-70 (23, 38) | DMD: 49-179 (33, 38)”
What the sources say
- Not checked yetcites [23] Cloyd, 1998, A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam, Epilepsia source
- Not checked yetcites [38] Kaplan, 1973, Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations, J Pharm Sci source
- Not checked yetcites [24] Anderson, 2002
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Midazolam | Versed | Yes | Anesthesia, preoperative and procedural | Second-line therapy for early status epilepticus”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clonazepam | Klonopin | Yes | Panic disorder, epileptic | Second-line adjunctive treatment for partial and”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Midazolam | Hydroxylation (CYP 3A4 and 3A5) (25, 41, 42) | 1-hydroxymidazolam (minor) (24) | 1-4 (24) | 1 (24)”
What the sources say
- Not checked yetcites [25] Hobbs, 1996
- Not checked yetcites [41] Gorski, 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily, Biochem Pharmacol source
- Not checked yetcites [42] Kronbach, 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4, Mol Pharmacol
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Diazepam | Valium | Yes | Anxiety, alcohol withdrawal, | First-line treatment for early status epilepticus;”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Lorazepam | Ativan | Yes | Anxiety, pre-anesthetic to induce amnesia, | First-line treatment for early status epilepticus”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
The paper relies on this without support.
Changes in simulated plasma DMD peak-to-trough concentrations correspond to clinical risks of breakthrough seizures and drug toxicity.
“This effect may prevent breakthrough seizures in some patients.”
“which may reduce the risk of drug toxicity.”
The paper relies on this without support.
Tolerance to antiepileptic drugs is associated with a progressive increase in the number and severity of seizures and an increased risk of withdrawal seizures when the maintenance dose is constant.
“Tolerance to AEDs is associated with a progressive increase in the number and severity of seizures and an increased risk of withdrawal seizures in the presence of a constant maintenance dose.”
The authors state this as an assumption.
In Bateson's unified model, initial potentiation of the GABA response leads to desensitization, and prolonged desensitization could result in uncoupling as either a signal for or a consequence of receptor internalization.
“This model assumes that initial potentiation of the GABA response leads to desensitization and that prolonged desensitization could result in uncoupling (as either a signal for or a consequence of receptor internalization, i.e. endocytosis).”
The authors state this as an assumption.
After receptor internalization, degradation of certain receptor subunits could provide a signal for changes in GABA A receptor gene transcription.
“Subsequent to receptor internalization, degradation of certain receptor subunits could provide a signal for changes in GABA A receptor gene transcription.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, the concomitant use of B. monnieri with clinically prescribed drugs that are substrates of CYP3A4, CYP2C9, and CYP2C19 isoforms, particularly those exhibiting poor bioavailability due to extensive metabolism such as clozapine [31] and midazolam [32] could cause potential herb-drug interactions.”
From Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents (2014) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Special formulations of BZDs
“These simulations were briefly described by Kaplan and DuPont (72), but detailed results are reported herein.”
§ References
“71. Kaplan EM, Dupont RL. Benzodiazepines and anxiety disorders: a review for the practicing physician. Curr Med Res Opin 2005;21:941-50.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metabolism and elimination
“short acting (<10 h; lorazepam, midazolam)”
§ Conclusions
“| Lorazepam | Glucuronidation (24) | NA | 7-26 (39, 40) | NA |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metabolism and elimination
“intermediate acting (10-24 h; clonazepam)”
§ Conclusions
“| Clonazepam | Nitroreduction (CYP 3A4), | NA | 19-60 (32) | NA |”
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Epilepsy: A Comprehensive Textbook
(2008) · JAMA · doi:10.1001/jama.300.4.443-a · Cited by 2,357
Macdonald, R. L., & Olsen, R. W. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.003033 · Cited by 1,975
A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus
Treiman, D. M., Meyers, P. D., Walton, N. Y., Collins, J. F., Colling, C., Rowan, A. J., Handforth, A., Faught, E., Calabrese, V. P., Uthman, B. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809173391202 · Cited by 1,325
Which GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
Alldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002141 · Cited by 888
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716
Jerram, T. C. (1981) · Side effects of drugs annual · doi:10.1016/s0378-6080(81)80009-8 · Cited by 695
Guidelines for the Rational Use of Benzodiazepines: When and What to Use
Ashton, H. (1994) · Drugs · doi:10.2165/00003495-199448010-00004 · Cited by 593
Greenblatt (1982) · doi:10.1056/nejm198205063061804 · Cited by 584
Study, R. E., & Barker, J. L. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.7180 · Cited by 564
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., & Meyer, U. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09118-7 · Cited by 532
Treatment of Convulsive Status Epilepticus
(1993) · JAMA · doi:10.1001/jama.1993.03510070076040 · Cited by 477
Epilepsy: A Comprehensive Textbook
(1998) · Archives of Neurology · doi:10.1001/archneur.55.10.1373 · Cited by 455
The importance of drug interactions in epilepsy therapy
Patsalos, P. N., Fröscher, W., Pisani, F., & Van Rijn, C. M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13001.x · Cited by 455
McIntyre, J., Robertson, S., Norris, E., Appleton, R., Whitehouse, W. P., Phillips, B., Martland, T., Berry, K., Collier, J., Smith, S., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66909-7 · Cited by 445
Principles of Neuropsychopharmacology
Feldman, R. S., Meyer, J. S., & Quenzer, L. F. (1997) · Cited by 444
The ABC of GABA receptors: a brief review
Chebib, M., & Johnston, G. A. R. (1999) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.1999.03151.x · Cited by 436
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
OGILVIE, R. I. (1983) · PubMed Central · Cited by 395
Scott, R. C., Besag, F. M., & Neville, B. G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06425-3 · Cited by 393
Management of drug therapy in the elderly
Desforges, J. F., Montamat, S. C., Cusack, B. J., & Vestal, R. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210507 · Cited by 388
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Double-blind study of lorazepam and diazepam in status epilepticus
Leppik, L. E. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03330350028021 · Cited by 354
Use of benzodiazepines in anxiety disorders
Wood, A. J. J., Shader, R. I., & Greenblatt, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281907 · Cited by 341
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Increased sensitivity to nitrazepam in old age
Castleden, C. M., George, C. F., Marcer, D., & Hallett, C. (1977) · BMJ · doi:10.1136/bmj.1.6052.10 · Cited by 320
Induction of CYP2C genes in human hepatocytes in primary culture.
Gerbal‐Chaloin, S., Pascussi, J., Pichard‐Garcia, L., Daujat‐Chavanieu, M., Waechter, F., Fabre, J.-M., Carrère, N., & Maurel, P. (2001) · PubMed · Cited by 318
Cognitive and sedative effects of benzodiazepine use
Buffett-Jerrott, S., & Stewart, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396654 · Cited by 312
Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis
Barker, M. (2004) · Archives of Clinical Neuropsychology · doi:10.1016/s0887-6177(03)00096-9 · Cited by 307
Rae, J. M., Johnson, M. D., Lippman, M. E., & Flockhart, D. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29202-8 · Cited by 307
Structure and subunit composition of GABAA receptors
Sieghart, W., Fuchs, K., Tretter, V, Ebert, V, Jechlinger, M., Höger, H., & Adamiker, D. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00045-5 · Cited by 306
Paradoxical reactions to benzodiazepines: literature review and treatment options
Mancuso, C. E., Tanzi, M. G., & Gabay, M. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1177.38089 · Cited by 298
(2004) · PubMed · Cited by 296
Lahat, E. (2000) · BMJ · doi:10.1136/bmj.321.7253.83 · Cited by 294
A comparison of rectal diazepam gel and placebo for acute repetitive seizures
Dreifuss, F. E., Rosman, N. P., Cloyd, J. C., Pellock, J. M., Kuzniecky, R. I., Lo, W. D., Matsuo, F., Sharp, G. B., Conry, J. A., Bergen, D. C., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382602 · Cited by 287
Self-citationLong-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.250.6.767 · Cited by 276
Long-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA · doi:10.1001/jama.1983.03340060045024 · Cited by 275
Ono, S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F. J., & Tsutsui, M. (1996) · Xenobiotica · doi:10.3109/00498259609046742 · Cited by 273
Pharmacokinetic Optimisation of Benzodiazepine Therapy for Acute Seizures: Focus on Delivery Routes
Rey, E., Tr??luyer, J.-M., & Pons, G. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00003 · Cited by 265
Amino acid pharmacology of mammalian central neurones grown in tissue culture
Barker, J. L., & Ransom, B. R. (1978) · The Journal of Physiology · doi:10.1113/jphysiol.1978.sp012387 · Cited by 265
Kaplan, S. A., Jack, M. L., Alexander, K., & Weinfeld, R. E. (1973) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600621111 · Cited by 260
Analysis of the set of GABAA receptor genes in the human genome
Simon, J., Wakimoto, H., Fujita, N., Lalande, M., & Barnard, E. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401354200 · Cited by 253
A Mechanistic Approach to Antiepileptic Drug Interactions
Anderson, G. D. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17332 · Cited by 249
Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240
McTague, A., Martland, T., & Appleton, R. E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001905.pub3 · Cited by 238
Andersson, T., Miners, J., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04336.x · Cited by 225
Mechanism of action of benzodiazepines on GABA A receptors
Campo‐Soria, C., Chang, Y., & Weiss, D. S. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706796 · Cited by 212
Pharmacokinetic drug interactions with oral contraceptives
Back, D. J., & Orme, M. L. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018060-00004 · Cited by 209
Shaner, D. M., McCurdy, S. A., Herring, M. O., & Gabor, A. J. (1988) · Neurology · doi:10.1212/wnl.38.2.202 · Cited by 207
Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans
Greenblatt, D. J., Shader, R. I., Franke, K., MacLaughlin, D. S., Harmatz, J. S., Allen, M. D., Werner, A., & Woo, E. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680119 · Cited by 197
LORAZEPAM VERSUS DIAZEPAM IN THE ACUTE TREATMENT OF EPILEPTIC SEIZURES AND STATUS EPILEPTICUS
Appletan, R., Sweeney, A., Choonara, I., Robson, J., & MOLYNEUX, E. M. (1995) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1995.tb15014.x · Cited by 194
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191
Children versus adults: pharmacokinetic and adverse-effect differences
Anderson, G. D. (2002) · Epilepsia · doi:10.1046/j.1528-1157.43.s.3.5.x · Cited by 187 · cited 2×
“Cytochrome P-450-catalyzed metabolism tends to be low at birth, but exceeds adult values by age 2–3 years; thereafter, CYP-catalyzed metabolism decreases, reaching adult levels around puberty (66).”
BackgroundChronic use of benzodiazepines and psychomotor and cognitive test performance
Lucki, I., Rickels, K., & Geller, A. (1986) · Psychopharmacology · doi:10.1007/bf00178503 · Cited by 186
Treatment of status epilepticus with diazepam (Valium)
GASTAUT, H., NAQUET, R., POIRÉ, R., & TASSINARI, C. A. (1965) · Epilepsia · doi:10.1111/j.1528-1157.1965.tb03786.x · Cited by 182
Court, M. H., Duan, S. X., Guillemette, C., Journault, K., Krishnaswamy, S., Moltke, L. L., & Greenblatt, D. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1257 · Cited by 174
Philip, W. P. (1948) · PubMed · Cited by 172
Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children
Mahmoudian, T., & Mohammadi Zadeh, M. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2004.01.003 · Cited by 171
Intravenous midazolam for the treatment of refractory status epilepticus
KUMAR, A., & BLECK, T. P. (1992) · Critical Care Medicine · doi:10.1097/00003246-199204000-00009 · Cited by 169
Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management
Schweizer, E., & Rickels, K. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05973.x · Cited by 163
Intranasal midazolam vs rectal diazepam in acute childhood seizures
Bhattacharyya, M., Kalra, V., & Gulati, S. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.09.006 · Cited by 152
Intravenous Midazolam for the Treatment of Refractory Status Epilepticus
Kumar, A., & Bleck, T. P. (1992) · Survey of Anesthesiology · doi:10.1097/00132586-199210000-00004 · Cited by 145
Wang, L., Zhou, G., Zhu, B. Y., Wu, J., Wang, J., El‐Aty, A. M. A., Li, T., Liu, J., Tian-lun, Y., Wang, D., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.014 · Cited by 145
Fişgin, T., Gurer, Y., Tezic, T., Senbil, N., Zorlu, P., Okuyaz, C., & Akgün, D. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700206 · Cited by 138
Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines
Kales, A. (1979) · JAMA · doi:10.1001/jama.241.16.1692 · Cited by 136
Continuous Midazolam Versus Diazepam Infusion for Refractory Convulsive Status Epilepticus
Singhi, S. C., Murthy, A., SINGHI, P. D., & Jayashree, M. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700203 · Cited by 134
Greenblatt, D. J., Divoll, M., Harmatz, J. S., & Shader, R. I. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710227 · Cited by 134
CLOBAZAM IN CATAMENIAL EPILEPSY
Feely, M., Calvert, R. T., & Gibson, J. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91691-9 · Cited by 121
Serum clonazepam concentrations in children with absence seizures
DREIFUSS, F. E., PENRY, J. K., ROSE, S. W., KUPFERBERG, H. J., DYKEN, P., & SATO, S. (1975) · Neurology · doi:10.1212/wnl.25.3.255 · Cited by 121
Treating repetitive seizures with a rectal diazepam formulation: A randomized study
Cereghino, J. J., Mitchell, W. G., Murphy, J., Kriel, R. L., Rosenfeld, W. E., Trevathan, E., & The North American Diastat Study Group* (1998) · Neurology · doi:10.1212/wnl.51.5.1274 · Cited by 119
Onof, S., Hatanaka, T., Miyazawa, S., Tsutsui, M., Aoyama, T., Gonzalez, F. J., & Satoh, T. (1996) · Xenobiotica · doi:10.3109/00498259609050260 · Cited by 118
Treatment of refractory generalized status epilepticus with continuous infusion of midazolam
Parent, J. M., & Lowenstein, D. H. (1994) · Neurology · doi:10.1212/wnl.44.10.1837 · Cited by 116
Diazepam elimination in premature and full term infants, and children
Morselli, P. L., Principi, N., Tognoni, G., Reali, E., Belvedere, G., Standen, S. M., & Sereni, F. (1973) · Journal of Perinatal Medicine · doi:10.1515/jpme.1973.1.2.133 · Cited by 116
Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray
Loftsson, T. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00580-9 · Cited by 116
Aggravation of epilepsy by anti-epileptic drugs
Gayatri, N., & Livingston, J. (2006) · Developmental Medicine & Child Neurology · doi:10.1017/s0012162206000843 · Cited by 114
Advances in epileptology: the XVth epilepsy international symposium
Hughes, J. R. (1985) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(85)90013-6 · Cited by 112
Pinder (1976) · doi:10.2165/00003495-197612050-00001 · Cited by 111
Mihic, S. J., Whiting, P. J., Klein, R. L., Wafford, K. A., & Harris, R. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)30057-0 · Cited by 110
Koch-Weser, J., & Browne, T. R. (1978) · New England Journal of Medicine · doi:10.1056/nejm197810122991505 · Cited by 106
Effective short-term diazepam prophylaxis in febrile convulsions
Knudsen, F. U. (1985) · The Journal of Pediatrics · doi:10.1016/s0022-3476(85)80688-0 · Cited by 104
Murphy, S. M., & Tyrer, P. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.511 · Cited by 104
Pharmacokinetics of single and multiple doses of clobazam in humans
Rupp, W., Badian, M., Christ, O., Hajdu, P., Kulkarni, R., Taeuber, K., Uihlein, M., Bender, R., & Vanderbeke, O. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb04665.x · Cited by 103
PLASMA CONCENTRATIONS OF MIDAZOLAM AFTER I.V., NASAL OR RECTAL ADMINISTRATION IN CHILDREN
Malinovsky, J. M., Lejus‐Bourdeau, C., Servin, F., Lepage, J.-Y., Normand, Y. L., TESTA, S., Cozian, A. Y., & Pinaud, M. (1993) · British Journal of Anaesthesia · doi:10.1093/bja/70.6.617 · Cited by 102
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
(1991) · Epilepsia · doi:10.1111/j.1528-1157.1991.tb04670.x · Cited by 102
Kales, A. (1979) · JAMA · doi:10.1001/jama.1979.03290420018017 · Cited by 101
Established anticonvulsants and treatment of refractory epilepsy
Brodie, M. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91886-f · Cited by 100
Lorazepam and diazepam effects on memory acquisition in priming tasks
Vidailhet, P., Danion, J.-M., Kauffmann-Muller, F., Grangé, D., Giersch, A., Van Der Linden, M., & Imbs, J.-L. (1994) · Psychopharmacology · doi:10.1007/bf02245083 · Cited by 96
Rational Use of Benzodiazepines in the Elderly
Shorr, R. I., & Robin, D. W. (1994) · Drugs & Aging · doi:10.2165/00002512-199404010-00002 · Cited by 92
N-Glucuronidation of Carbamazepine in Human Tissues Is Mediated by UGT2B7
Staines, A. G., Coughtrie, M. W. H., & Burchell, B. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073114 · Cited by 92
Benzodiazepine withdrawal: a review of the evidence.
Noyes, R., Garvey, M. J., Cook, B. L., & Perry, P. J. (1988) · PubMed · Cited by 87
Kinetics and metabolism of clobazam in animals and man
Volz, M., Christ, O., Kellner, H., Kuch, H., Fehlhaber, H., Gantz, D., Hajdu, P., & Cavagna, F. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb04664.x · Cited by 85
Treatment of Status Epilepticus with a new Benzodiazepine More Active than Diazepam*
Gastaut, H., Courjon, J., Poiré, R., & Weber, M. (1971) · Epilepsia · doi:10.1111/j.1528-1157.1971.tb04928.x · Cited by 82
Cloyd, J. C., Lalonde, R. L., Beniak, T. E., & Novack, G. D. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01415.x · Cited by 81
Self-citationClobazam as adjunctive treatment in refractory epilepsy.
Allen, J. W., Oxley, J. R., Robertson, M. M., Trimble, M., Richens, A., & Jawad, S. (1983) · BMJ · doi:10.1136/bmj.286.6373.1246 · Cited by 81
Benzodiazepine Withdrawal Syndrome: A Literature Review and Evaluation
Mackinnon, G. L., & Parker, W. A. (1982) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998209002608 · Cited by 81
Rectal Diazepam Gel for Treatment of Acute Repetitive Seizures in Adults
Cereghino, J. J. (2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1915 · Cited by 81
Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912002-00005 · Cited by 80
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam
Kosaki, K., Tamura, K., Sato, R., Samejima, H., Tanigawara, Y., & Takahashi, T. (2004) · Brain and Development · doi:10.1016/j.braindev.2004.02.010 · Cited by 80
Development of tolerance to the anticonvulsant effect of diazepam in dogs
Frey, H.-H., Philippin, H.-P., & Scheuler, W. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90365-0 · Cited by 80
Nelson, J., & Chouinard, G. (1999) · PubMed · Cited by 79
Smith, R. B., & Kroboth, P. D. (1987) · Psychopharmacology · doi:10.1007/bf02439595 · Cited by 76
Koeppen, D., Baruzzi, A., Capozza, M., Chauvel, P., Courjon, J., Favel, P., Harmant, J., Lorenz, H. E., Oiler, F. V. L., Procaccianti, G., et al. (1987) · Epilepsia · doi:10.1111/j.1528-1157.1987.tb03678.x · Cited by 76
Berlin, A., & Dahlstr�m, H. (1975) · European Journal of Clinical Pharmacology · doi:10.1007/bf00614012 · Cited by 74
Benzodiazepine Dependence: Avoidance and Withdrawal
Marriott, S., & Tyrer, P. (1993) · Drug Safety · doi:10.2165/00002018-199309020-00003 · Cited by 73
Rectal diazepam gel for treatment of acute repetitive seizures
Kriel, R. L., Cloyd, J. C., Pellock, J. M., Mitchell, W. G., Cereghino, J. J., & Rosman, N. P. (1999) · Pediatric Neurology · doi:10.1016/s0887-8994(98)00156-8 · Cited by 68
Self-citationDifferences between the tolerance characteristics of two anticonvulsant benzodiazepines
Gent, J. P., Feely, M. P., & Haigh, J. R. M. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90520-x · Cited by 66
Seizures induced by abrupt discontinuation of alprazolam
Breier, A. F., Charney, D. S., & Nelson, J. C. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.12.1606 · Cited by 65
Home and hospital treatment of acute seizures in children with nasal midazolam
Jeannet, P., Roulet, E., Maeder‐Ingvar, M., Gehri, M., Jutzi, A., & Deonna, T. W. (1999) · European Journal of Paediatric Neurology · doi:10.1016/s1090-3798(99)80016-6 · Cited by 64
Pellock, J. M., Smith, M. C., Cloyd, J. C., Uthman, B., & Wilder, B. J. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2004.01.009 · Cited by 64
Self-citationTolerance to the anti-pentylenetetrazole effects of diazepam in the mouse
File, S. E. (1983) · Psychopharmacology · doi:10.1007/bf00427828 · Cited by 62
The cognitive and behavioural effects of clobazam and standard monotherapy are comparable
Bawden, H. N., Camfield, C. S., Camfield, P. R., Cunningham, C., Darwish, H., Dooley, J. M., Gordon, K., Ronen, G., Stewart, J., & van Mastrigt, R. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(98)00088-6 · Cited by 61
Clobazam for Refractory Focal Epilepsy: A Controlled Trial
Schmidt, D. (1986) · Archives of Neurology · doi:10.1001/archneur.1986.00520080064023 · Cited by 60
Treatment of epilepsy with clonazepam and its effect on other anticonvulsants
Nanda, R. N., Johnson, R. H., Keogh, H. J., Lambie, D. G., & Melville, I. D. (1977) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.40.6.538 · Cited by 60
Midazolam as an induction agent in children: a pharmacokinetic and clinical study.
SALONEN, M. A. O., Kanto, J., Iisalo, E., et al. (1987) · PubMed · Cited by 59
Drug related falls: a study in the French pharmacovigilance database
Souchet, E., Lapeyre‐Mestre, M., & Montastruc, J. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1038 · Cited by 59
Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism
Seree, E., Pisano, P., Placidi, M., Rahmani, R., & Barra, Y. (1993) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1993.tb00219.x · Cited by 59
Intrarectal diazepam in epileptic adults
Remy, C., Jourdil, N., Villemain, D., Favel, P., & Genton, P. (1992) · Epilepsia · doi:10.1111/j.1528-1157.1992.tb02327.x · Cited by 58
Ulvi, H., Yoldaş, T. K., M�ngen, B., & Yiğiter, R. (2002) · Neurological Sciences · doi:10.1007/s100720200058 · Cited by 58
Development of tolerance to the anticonvulsant effect of diazepam in amygdala-kindled rats
Löscher, W., & Schwark, W. S. (1985) · Experimental Neurology · doi:10.1016/0014-4886(85)90026-3 · Cited by 57
Midazolam as an Induction Agent in Children: A Pharmacokinetic and Clinical Study
Salonen, M., Kanto, J., lisalo, E., & Himberg, J.-J. (1987) · Anesthesia & Analgesia · doi:10.1213/00000539-198707000-00007 · Cited by 57
Patients conscious recollections from cardiac anesthesia
Ranta, S. O.-V., Herranen, P., & Hynynen, M. (2002) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/jcan.2002.125149 · Cited by 56
Clinical pharmacology of benzodiazepines
Lader, M. (1987) · Annual Review of Medicine · doi:10.1146/annurev.me.38.020187.000315 · Cited by 56
Pharmacokinetics of benzodiazepines. Short-acting versus long-acting.
Breimer, D. D., Jochemsen, R., & von Albert, H. H. (1980) · PubMed · Cited by 55
Benzodiazepines and anxiety disorders: a review for the practicing physician
Kaplan, E. M., & DuPont, R. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x48401 · Cited by 55
The dependence potential of short half-life benzodiazepines: a meta-analysis
Hallfors, D. D., & Saxe, L. (1993) · American Journal of Public Health · doi:10.2105/ajph.83.9.1300 · Cited by 54
Managing alcohol withdrawal in the elderly
Kraemer, K. L., Conigliaro, J., & Saitz, R. (1999) · Drugs & Aging · doi:10.2165/00002512-199914060-00002 · Cited by 53
Eight-year study of childhood status epilepticus: midazolam infusion in management and outcome
Koul, R., Chako, A., Javed, H., & Riyami, K. A. (2002) · Journal of Child Neurology · doi:10.1177/08830738020170123002 · Cited by 53
Use of diazepam in treatment of severe convulsive status epilepticus.
Parsonage, M. J., & Norris, J. W. (1967) · BMJ · doi:10.1136/bmj.3.5557.85 · Cited by 52
Clinically significant pharmacokinetic drug interactions with benzodiazepines
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00247.x · Cited by 52
Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood
Keene, D. L., Whiting, S., & Humphreys, P. (1990) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100030651 · Cited by 52
Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory
Legrand, F., Vidailhet, P., Danion, J. M., Giersch, A., Grangé, D., Van Der Linden, M., & Imbs, J. L. (1995) · Psychopharmacology · doi:10.1007/bf02245949 · Cited by 49
Tolerance to anticonvulsant effects of diazepam, clonazepam, and clobazam in amygdala-kindled rats
Rosenberg, H. C., Tietz, E. I., & Chiu, T. H. (1989) · Epilepsia · doi:10.1111/j.1528-1157.1989.tb05299.x · Cited by 48
Greenblatt, D. J., Divoll, M. K., Soong, M. H., Boxenbaum, H. G., Harmatz, J. S., & Shader, R. I. (1988) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1988.tb03228.x · Cited by 42
Guðmundsdóttir, H., Sigurjónsdóttir, J. F., Másson, M., Fjalldal, O., Stefánsson, E., & Loftsson, Þ. (2001) · PubMed · Cited by 42
Appleton, R., Martland, T., & Phillips, B. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001905 · Cited by 42
Nasal Midazolam Effects on Childhood Acute Seizures
Fişgin, T., Gürer, Y., Şenbil, N., Teziç, T., Zorlu, P., Okuyaz, Ç., & Akgün, D. (2000) · Journal of Child Neurology · doi:10.1177/088307380001501219 · Cited by 41
Milligan, N. M., Dhillon, S., Griffiths, A., Oxley, J., & Richens, A. (1984) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.47.3.235 · Cited by 41
Combination therapy for status epilepticus: intravenous diazepam and phenytoin.
Delgado‐Escueta, A. V., & Enrile-Bacsal, F. (1983) · PubMed · Cited by 41
Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations
Guberman, A., Couture, M., Blaschuk, K., & Sherwin, A. (1990) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710003064x · Cited by 40
Sugai, K. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.458005.x · Cited by 39
Northern epilepsy syndrome: clinical course and the effect of medication on seizures
Hirvasniemi, A., Herrala, P., & Leisti, J. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01616.x · Cited by 39
Wagemans, J., Notebaert, W., & Boucart, M. (1998) · Psychopharmacology · doi:10.1007/s002130050678 · Cited by 38
Withdrawal symptoms from high dose benzodiazepines in poly drug users
Seivewright, N., & Dougal, W. (1993) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(93)90018-l · Cited by 38
Seizures Following the Withdrawal of Alprazolam
Noyes, R., Perry, P. J., Crowe, R., Coryell, W. H., CLANCY, J., Yamada, T., & Gabel, J. (1986) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198601000-00009 · Cited by 38
Wassmer, E., Qureshi, A. M., Davies, P. A., Berry, K., & Whitehouse, W. P. (2002) · Seizure · doi:10.1053/seiz.2001.0635 · Cited by 38
THE USE OF CLONAZEPAM AS AN ANTICONVULSANT—CLINICAL EVALUATION
Bladin, P. F. (1973) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1973.tb110623.x · Cited by 38
High-dose intravenous lorazepam for the treatment of refractory status epilepticus
Labar, D. R., Ali, A., & Root, J. (1994) · Neurology · doi:10.1212/wnl.44.8.1400 · Cited by 37
Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing
Kroboth, P. D., McAuley, J. W., & Smith, R. B. (1990) · Psychopharmacology · doi:10.1007/bf02243999 · Cited by 35
Comparative trial of intravenous lorazepam and clonazepam im status epilepticus.
Sorel, L., Mechler, L., & Harmant, J. (1981) · PubMed · Cited by 34
Garratt, J. C., Paul Gent, J., Feely, M., & Haigh, J. R. M. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90351-2 · Cited by 34
A double-blind study of clonazepam in the treatment of therapy-resistant epilepsy in children
Bensch, J., Blennow, G., Ferngren, H., Gamstorp, I., Herrlin, K. ‐., Kubista, J., Arvidsson, A., & Dahlström, H. (1977) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1977.tb08369.x · Cited by 33
Effects of lorazepam and diazepam on conscious and automatic memory processes
Vidailhet, P., Kazès, M., Danion, J., Kauffmann-Muller, F., & Grangé, D. (1996) · Psychopharmacology · doi:10.1007/bf02805976 · Cited by 33
Clobazam: pharmacological and therapeutic profile
Hanks, G. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb04685.x · Cited by 32
Clorazepate and phenobarbital as antiepileptic drugs: A double‐blind study
Wilensky, A. J., Ojemann, L. M., Temkin, N. R., Troupin, A. S., & Dodrill, C. B. (1981) · Neurology · doi:10.1212/wnl.31.10.1271 · Cited by 32
Ramsey-Williams, V. A., Wu, Y., & Rosenberg, H. C. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90344-1 · Cited by 31
Gobbi, M., Barone, D., Mennini, T., & Garattini, S. (1987) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1987.tb03404.x · Cited by 31
Pharmacokinetic Considerations in Prescribing Antiepileptic Drugs
Faught, E. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00004.x · Cited by 29
Intermittent prophylaxis in febrile convulsions: diazepam or valproic acid?
Daugbjerg, P., Brems, M., Mai, J., Ankerhus, J., & Knudsen, F. U. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1990.tb01581.x · Cited by 28
Martin, D., & Hirt, H. R. (1973) · Neuropediatrics · doi:10.1055/s-0028-1091744 · Cited by 28
Factors relating to dramatic response to clobazam therapy in refractory epilepsy
Heller, A. J., Ring, H. A., & Reynolds, E. H. (1988) · Epilepsy Research · doi:10.1016/0920-1211(88)90020-4 · Cited by 27
The use of clobazam, midazolam, and nitrazepam in epilepsy
Shorvon, S. D. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb05109.x · Cited by 27
Session on Multiple Sclerosis Morning Meeting Friday, April 29, 1977
(1977) · Neurology · doi:10.1212/wnl.27.4.371 · Cited by 27
Clonazepam acetylation in fast and slow acetylators
Miller, M. E., Garland, W. A., Min, B. H., Ludwick, B. T., Ballard, R. H., & Levy, R. H. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.170 · Cited by 26
Ochs, H. R., Steinhaus, E., Locniskar, A., Knüchel, M., & Greenblatt, D. J. (1982) · Journal of Molecular Medicine · doi:10.1007/bf01735933 · Cited by 25
Evaluation of clorazepate (Tranxene®) as an anticonvulsant—a pilot study
Troupin, A. S., Friel, P. N., Wilensky, A. J., Ojemann, L. M., Levy, R. H., & Feigl, P. (1979) · Neurology · doi:10.1212/wnl.29.4.458 · Cited by 25
Benzodiazepines in the treatment of epilepsy in people with intellectual disability.
Isojärvi, J. I. T., & Tokola, R. A. (1998) · PubMed · Cited by 24
Clorazepate in dogs: tolerance to the anticonvulsant effect and signs of physical dependence
Scherkl, R., Kurudi, D., & Frey, H.-H. (1989) · Epilepsy Research · doi:10.1016/0920-1211(89)90042-9 · Cited by 24
Rey, E., Giraux, P., d'Athis, P., Turquais, J. M., Chavinie, J., & Olive, G. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00563103 · Cited by 24
Li, M., Szabo, A., & Rosenberg, H. C. (2000) · PubMed · Cited by 24
Atack, J. R., Pike, A., Clarke, A., Cook, S. M., Sohal, B., McKernan, R. M., & Dawson, G. R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006973 · Cited by 23
Young, N. A., Lewis, S. J., Harris, Q. L. G., Jarrott, B., & Vajda, F. J. E. (1988) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1988.tb05269.x · Cited by 22
Shader, R. I., Rj, P., Harmatz, J. S., Allison, S. J., Locniskar, A., & Greenblatt, D. J. (1984) · PubMed · Cited by 21
Pharmacokinetic Considerations in Prescribing Antiepileptic Drugs
Faught, E. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.0420s4019.x · Cited by 20
Clorazepate dipotassium in the treatment of intractable epilepsy
Booker, H. E. (1974) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1974.03230430044026 · Cited by 19
Lorazepam: a controlled trial in patients with intractable partial complex seizures
Walker, J. E., Homan, R. W., & Crawford, I. L. (1984) · Epilepsia · doi:10.1111/j.1528-1157.1984.tb03444.x · Cited by 19
Tolerance to the Anticonvulsant Effect of Clorazepate and Clonazepam in Mice
Scherkl, R., Kurudi, D., & Frey, H. ‐. (1988) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1988.tb01841.x · Cited by 18
An 87-year-old woman taking a benzodiazepine
Salzman, C. (1999) · JAMA · doi:10.1001/jama.281.12.1121 · Cited by 18
Ventura, A., Basso, T., Bortolan, G., Gardini, A., Guidobaldi, G., Russo, G. L., Marinoni, S., Merli, A., Messi, G., Mussi, G., et al. (1982) · PubMed · Cited by 18
Benzodiazepine withdrawal syndrome seizures
Martínez-Cano, H., Vela-Bueno, A., de Iceta, M., Pomalima, R., & Martínez-Gras, I. (1995) · Pharmacopsychiatry · doi:10.1055/s-2007-979613 · Cited by 17
On the use of tranquillisers in epilepsy
Trimble, M. R. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.043s2025.x · Cited by 16
Clorazepate therapy for refractory seizures
Berchou, R. C., Rodin, E. A., & Russell, M. E. (1981) · Neurology · doi:10.1212/wnl.31.11.1483 · Cited by 16
Scott (2001) · doi:10.1136/bmj.322.7278.107 · Cited by 16
Benzodiazepines: Some Aspects of Their Clinical Pharmacology
Shader, R. I., & Greenblatt, D. J. (1980) · Novartis Foundation symposium · doi:10.1002/9780470720578.ch9 · Cited by 15
Polymorphic acetylation of 7-amino-clonazepam in human liver cytosol.
Peng, D.-R., Birgersson, C., von Bahr, C., & Rane, A. (1984) · PubMed · Cited by 14
Kanto, J., Sellman, R., Haataja, M., & Hurme, P. (1978) · PubMed · Cited by 13
Antiepileptic effect and serum levels of clorazepate on children with refractory seizures
Mimaki, T., Tagawa, T., Ono, J., Tanaka, J., Terada, H., Itoh, N., & Yabuuchi, H. (1984) · Brain and Development · doi:10.1016/s0387-7604(84)80097-2 · Cited by 12
High-risk drugs in the elderly population
Demaagd, G. (1995) · Geriatric Nursing · doi:10.1016/s0197-4572(05)80161-2 · Cited by 9
Pharmacokinetics of dipotassium chlorazepate in patients after repeated 50 mg oral doses
Bertler, �., Lindgren, S., & Malmgren, H. (1980) · Psychopharmacology · doi:10.1007/bf00434406 · Cited by 8
Continuous infusion of diazepam in infants with severe recurrent convulsions.
Thong, Y. H., & Dc, A. (1974) · PubMed · Cited by 8
Excellent results with clorazepate in recalcitrant childhood epilepsies
Naidu, S., Gruener, G., & Brazis, P. (1986) · Pediatric Neurology · doi:10.1016/0887-8994(86)90034-2 · Cited by 6
Ketz, E., Bernoulli, C., & Siegfried, J. (1973) · PubMed · Cited by 6
Clorazepate therapy for intractable epilepsy
Fujii, T., Okuno, T., Go, T., Ochi, J., Hattori, H., Kataoka, K., & Mikawa, H. (1987) · Brain and Development · doi:10.1016/s0387-7604(87)80046-3 · Cited by 5
[Treatment of status epilepticus with Rivotril].
Ketz, E. (1973) · PubMed · Cited by 4
[Clinical use and effect of Ro 5-4023 (clonazepam) in different forms of epileptic seizures].
Kruse, R., & Blankenhorn (1973) · PubMed · Cited by 4
International Narcotics Control Board (2016) · Statistics on psychotropic substances for ... · doi:10.18356/d7854af5-en-fr-es · Cited by 4
Research works printed but not linked: 26
- International Narcotics Control Board, Psychotropic Substances 2006
- Shorvon, 1995, Antiepileptic drugs, 763
- Anderson, 2002, Antiepileptic drugs, 187
- Hobbs, 1996, Goodman & Gilmans. The pharmacological basis of therapeutics, 361
- United Nations, 1997, Recommended methods for the detection and assay of barbiturates and benzodiazepines in biological specimens. Manual for use by national laboratories
- Flockhart, Drug interaction table (cytochrome P450 system)
- 47.Trileptal [package insert]. East Hanover, NJ: Novartis, 2007.
- Lacy, Anticonvulsants and antimicrobial cytochrome P-450 effects
- Goshman, 1999, Clinically significant P450 drug interactions, J Pharm Soc Wisconsin, 23
- Riss, The simulation of desmethyldiazepam (DMD) concentrations following missed daily doses of Tranxene-SD and Tranxene T-Tab
- Gastaut, 1965, Laction du diazepam (Valium) dans le traitement des formes non-convulsive de lepilepsie generalisee [in French], Rev Neurol (Paris), 112, 99
- Schmidt, 2002, Antiepileptic drugs, 206
- Schmidt, 1995, Antiepileptic drugs, 705
- Sato, 1995, Antiepileptic drugs, 725
- Sato, 1977, Clonazepam in the treatment of absence seizures: a double-blind clinical trial [abstract], Neurology, 27, 371
- Beck, 1973, Traitement des etats de mal epileptiques par le clonazepam [in French], Sem Hop Paris, 49, 21
- Bergamini, 1970, Elektroenzephalographische und klinische Bewertung des neuen Benzodiazepin Ro 54023 [in German], EEG EMG, 1, 182
- Bergamini, 1972, LAction du Ro 54023 dans le traitement des differentes formes depilepsie [in French]
- Gastaut, 1970, Properties anti-epileptiques exceptionneles dune benzodiazepine nouvelle le Ro 05-4023 [in French], La Vie Medicale, 51, 5175
- Gimenez-Roldan, 1972, Un nuevo medicamento eficaz en el trataimento del status epilepticus - Ro 5-4023 [in Spanish], Med Clin (Barc), 58, 133
- Tridon, 1973, Conduite du traitement des etats de mal epileptiques par le Ro 05-4023 (clonazepam) [in French], Sem Hop Paris, 49, 29
- 123.Midazolam HCl injection [package insert]. Weston, FL: Apotex Corp, 2000.
- Wolf, 1985, Clobazam. Human psychopharmacology and clinical application, 167
- Critchley, 1981, Clobazam, 159
- Wilson, 1985, Clobazam. Human psychopharmacology and clinical application, 172
- Graf, 1987, Clorazepate therapy in children with refractory seizures [abstract], Epilepsia, 28, 606
Cited by
Sorted by citations
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 335
Bohrey, S., Chourasiya, V., & Pandey, A. (2016) · Nano Convergence · doi:10.1186/s40580-016-0061-2 · Cited by 284
Alcohol withdrawal syndrome: mechanisms, manifestations, and management
Jesse, S., Bråthen, G., Ferrara, M., Keindl, M., Ben‐Menachem, E., Tănăsescu, R., Brodtkorb, E., Hillbom, M., Leone, M. A., & Ludolph, A. C. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12671 · Cited by 261
Pain Assessment and Treatment in Children With Significant Impairment of the Central Nervous System
Hauer, J., Houtrow, A. J., Feudtner, C., Klein, S. M., Klick, J. C., Linebarger, J., Norwood, K. W., Adams, R. C., Brei, T. J., Davidson, L. F., et al. (2017) · PEDIATRICS · doi:10.1542/peds.2017-1002 · Cited by 230
Metadata
- Authors
- Riss, J., Cloyd, J., Gates, J., & Collins, S.
- Affiliations
- University of Minnesota (US)
- Minnesota Epilepsy Group (US)
- Corresponding author
- Cloyd, J.
- ORCID
- Cloyd, J.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Wiley
- Published
- 2008-08
- Volume
- 118
- Issue
- 2
- Pages
- 69-86
- ISSN
- 0001-6314 (ISSN-L)
- 1600-0404
- OpenAlex
- W2047978949
- Cited by
- 511
- References
- 205
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 30 · 2023: 26 · 2022: 25 · 2021: 26 · 2020: 40 · 2019: 36 · 2018: 33 · 2017: 25 · 2016: 37 · 2015: 30 · 2014: 39 · 2013: 23 · 2012: 38
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Acta Neurologica Scandinavica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- benzodiazepines, epilepsy, pharmacokinetics, pharmacology, clorazepate, clonazepam, diazepam, lorazepam, midazolam, clobazam, drug tolerance, drug interactions, sedation, cognitive impairment, status epilepticus, febrile seizures, alcohol withdrawal seizures
- MeSH terms
- Benzodiazepines, Epilepsy, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
